Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Tango Therapeutics to post earnings of ($0.3182) per share and revenue of $0.50 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Trading Up 0.5%

Tango Therapeutics stock opened at $19.42 on Monday. The firm has a market capitalization of $2.77 billion, a price-to-earnings ratio of -22.32 and a beta of 1.76. The firm’s fifty day moving average price is $13.49 and its two-hundred day moving average price is $10.26. Tango Therapeutics has a 1-year low of $1.03 and a 1-year high of $19.81.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TNGX. Jefferies Financial Group restated a “buy” rating and issued a $18.00 target price on shares of Tango Therapeutics in a report on Thursday, March 5th. Wedbush boosted their price objective on Tango Therapeutics from $15.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Stifel Nicolaus increased their price objective on Tango Therapeutics from $15.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Mizuho raised their target price on Tango Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, March 11th. Finally, HC Wainwright lifted their target price on Tango Therapeutics from $13.00 to $27.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $19.50.

Insider Activity at Tango Therapeutics

In related news, Director Barbara Weber sold 30,519 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the transaction, the director directly owned 1,629,254 shares in the company, valued at approximately $19,974,654.04. The trade was a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Daniella Beckman sold 10,317 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $126,486.42. Following the completion of the sale, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at $2,259,481.22. The trade was a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 133,884 shares of company stock valued at $1,724,622 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.

Hedge Funds Weigh In On Tango Therapeutics

Several institutional investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of Tango Therapeutics during the fourth quarter valued at approximately $335,000. VARCOV Co. purchased a new position in Tango Therapeutics in the fourth quarter worth $261,000. Virtus Investment Advisers LLC grew its stake in Tango Therapeutics by 26.3% in the 4th quarter. Virtus Investment Advisers LLC now owns 28,452 shares of the company’s stock valued at $252,000 after purchasing an additional 5,920 shares during the period. Tudor Investment Corp ET AL grew its stake in Tango Therapeutics by 27.4% in the 4th quarter. Tudor Investment Corp ET AL now owns 68,251 shares of the company’s stock valued at $605,000 after purchasing an additional 14,679 shares during the period. Finally, Sphera Funds Management LTD. purchased a new stake in shares of Tango Therapeutics during the 4th quarter valued at $4,825,000. 78.99% of the stock is owned by institutional investors.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.